Search Results - Baselga, J.

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

    PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer by Serra, V., Scaltriti, M., Prudkin, L., Eichhorn, Pieter, Ibrahim, Y.H., Chandarlapaty, S., Markman, B., Rodriguez, O., Guzman, M., Rodriguez, S., Gili, M., Russillo, M., Parra, J.L., Singh, S., Arribas, J., Rosen, N., Baselga, J.

    Published 2011
    Get full text
  2. 2
    Erratum: RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer (Journal of Clinical Investigation (2013) 123:6 (2551-2563) DOI:10.1172/JCI66343)

    Erratum: RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer (Journal of Clinical Investigation (2013) 123:6 (2551-2563) DOI:10.1172/JCI66343) by Serra, V., Eichhorn, Pieter, García-García, C., Ibrahim, Y., Prudkin, L., Sánchez, G., Rodríguez, O., Antón, P., Parra, J., Marlow, S., Scaltriti, M., Pérez-Garcia, J., Prat, A., Arribas, J., Hahn, W., Kim, S., Baselga, J.

    Published 2014
    Get full text
  3. 3
    Randomized Phase 11 Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatis Triple-Negative Breast Cancer

    Randomized Phase 11 Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatis Triple-Negati... by Baselga, J., Gomez, P., Greil, R., Braga, S., Climent, M., Wardley, A., Kaufman, B., Stemmer, S., Pego, A., Chan, Arlene, Goeminne, J., Graas, M., Kennedy, J., Ciruelos, E.M., Schneeweiss, A., Zubel, A., Groos, J., Melezinkova, H., Awada, A.

    Published 2013
    Get full text
  4. 4
    RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer

    RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast C... by Baselga, J., Zamagni, C., Gómez, P., Bermejo, B., Nagai, S., Melichar, B., Chan, Arlene, Mángel, L., Bergh, J., Costa, F., Gómez, H., Gradishar, W., Hudis, C., Rapoport, B., Roché, H., Patricia, M., Huang, L., Meinhardt, G., Zhang, J., Schwartzberg, L.

    Published 2017
    Get full text

Search Tools: